Comments

BioAtla Analyst Ratings

BCABNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$0.7601

-0.0122-1.58%

At close: Dec 16, 4:00 PM EST

$0.7680

0.00791.04%

After Hours: 4:08 PM EST

Overview News Earnings Options

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$25.00

Lowest Price Target¹

$1.00

Consensus Price Target¹

$11.00

BioAtla Analyst Ratings and Price Targets | NASDAQ:BCAB | Benzinga

BioAtla Inc has a consensus price target of $11 based on the ratings of 8 analysts. The high is $25 issued by EF Hutton on August 2, 2023. The low is $1 issued by Citizens Capital Markets on March 31, 2025. The 3 most-recent analyst ratings were released by Citizens Capital Markets, JMP Securities, and JMP Securities on March 31, 2025, September 16, 2024, and May 23, 2024, respectively. With an average price target of $3.67 between Citizens Capital Markets, JMP Securities, and JMP Securities, there's an implied 377.43% upside for BioAtla Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Citizens Capital Markets

JMP Securities

JP Morgan

EF Hutton

BTIG

¹calculated from analyst ratings

Analyst Ratings for BioAtla

					Get Alert
Aug 13, 2025	—	Reni J. BenjaminJMP Securities 50%	—	Previous Market Outperform Current Market Perform	Get Alert
Mar 31, 2025	30.21%	Reni BenjaminCitizens Capital Markets 45%	1 5	Previous Market Outperform Current Market Outperform	Get Alert
Mar 31, 2025	—	Arthur HeHC Wainwright & Co. 69%	—	Previous Neutral Current Neutral	Get Alert
Nov 13, 2024	—	Arthur HeHC Wainwright & Co. 69%	—	Previous Buy Current Neutral	Get Alert
Sep 16, 2024	551.04%	Reni BenjaminJMP Securities 45%	5 5	Previous Market Outperform Current Market Outperform	Get Alert
May 23, 2024	551.04%	Reni BenjaminJMP Securities 45%	5 12	Previous Market Outperform Current Market Outperform	Get Alert
May 15, 2024	811.46%	Arthur HeHC Wainwright & Co. 69%	7 7	Previous Buy Current Buy	Get Alert
Mar 28, 2024	1462.5%	Reni BenjaminJMP Securities 45%	12 12	Previous Market Outperform Current Market Outperform	Get Alert
Mar 27, 2024	811.46%	Arthur HeHC Wainwright & Co. 69%	7 10	Previous Buy Current Buy	Get Alert
Dec 5, 2023	1462.5%	Reni BenjaminJMP Securities 45%	12	Previous Market Outperform Current Market Outperform	Get Alert
Nov 8, 2023	1202.08%	Arthur HeHC Wainwright & Co. 69%	10 17	Previous Buy Current Buy	Get Alert
Sep 25, 2023	1722.92%	Brian ChengJP Morgan 49%	14 17	Previous Overweight Current Overweight	Get Alert
Aug 2, 2023	2113.54%	Brian ChengJP Morgan 49%	17 19	Previous Overweight Current Overweight	Get Alert
Aug 2, 2023	1462.5%	Reni BenjaminJMP Securities 45%	12	Previous Market Outperform Current Market Outperform	Get Alert
Aug 2, 2023	3155.21%	Tony ButlerEF Hutton 41%	25	Previous Buy Current Buy	Get Alert
Aug 2, 2023	2113.54%	Arthur HeHC Wainwright & Co. 69%	17	Previous Buy Current Buy	Get Alert
May 15, 2023	1462.5%	Reni BenjaminJMP Securities 45%	12 12	Previous Outperform Current Outperform	Get Alert
May 15, 2023	2113.54%	Arthur HeHC Wainwright & Co. 69%	17	Previous Buy Current Buy	Get Alert
May 12, 2023	3155.21%	Tony ButlerEF Hutton 41%	25	Previous Buy Current Buy	Get Alert
Apr 17, 2023	3155.21%	Tony ButlerEF Hutton 41%	25	Previous Current Buy	Get Alert
Apr 3, 2023	2373.96%	Brian ChengJP Morgan 49%	19 23	Previous Current Overweight	Get Alert
Mar 28, 2023	1592.71%	Thomas ShraderBTIG 57%	13 68	Previous Current Buy	Get Alert
Mar 27, 2023	1462.5%	Reni BenjaminJMP Securities 45%	12 17	Previous Current Outperform	Get Alert
Mar 24, 2023	941.67%	Tiago FauthCredit Suisse 57%	8	Previous Current Neutral	Get Alert
Mar 24, 2023	3155.21%	Tony ButlerEF Hutton 41%	25	Previous Current Buy	Get Alert
Mar 24, 2023	2113.54%	Arthur HeHC Wainwright & Co. 69%	17 20	Previous Current Buy	Get Alert
Jan 5, 2023	3155.21%	Tony ButlerEF Hutton 41%	25	Previous Initiates Current Buy	Get Alert

FAQ

What is the target price for BioAtla (BCAB) stock?

The latest price target for BioAtla (NASDAQ:BCAB) was reported by JMP Securities on August 13, 2025. The analyst firm set a price target for $0.00 expecting BCAB to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for BioAtla (BCAB)?

The latest analyst rating for BioAtla (NASDAQ:BCAB) was provided by JMP Securities, and BioAtla downgraded their market perform rating.

When was the last upgrade for BioAtla (BCAB)?

There is no last upgrade for BioAtla

When was the last downgrade for BioAtla (BCAB)?

The last downgrade for BioAtla Inc happened on August 13, 2025 when JMP Securities changed their price target from N/A to N/A for BioAtla Inc.

When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on August 13, 2025 so you should expect the next rating to be made available sometime around August 13, 2026.

Is the Analyst Rating BioAtla (BCAB) correct?

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a downgraded with a price target of $0.00 to $0.00. The current price BioAtla (BCAB) is trading at is $0.77, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.